Additionally, glucagon-like peptide 1 receptor agonists (GLP-1 RAs) may also reduce weight and prevent T2DM in patients with obesity [56,57]. This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.